Our pipeline

rad clinical development pipeline

Read more about our clinical trials below
Nano-mAbs Clinical Trials

HER-2 PHASE 1 BREAST IMAGING COMPLETE

Phase 1 imaging has been completed on 33 patients with Technetium-99m in Shanghai and Germany
  • Non-invasive and demonstrated safety
  • Accumulation / high uptake in target within 2 hours post injection
  • Acceptable biodistribution and dosimetry (renal protection can be achieved by standard pre-injection of gelufusin/amino acids mixture)
  • Shows clear intra and inter-tumoural heterogeneity of HER-2 expression
  • Provide more accurate and informative information on HER-2 cancers in comparison to existing IHC / FISH detections from biopsy samples
  • Potential to be used for whole body assessment and treatment of HER-2+ cancers with different medical radioisotopes

HER-2 PHASE 1 BREAST THERAPEUTIC COMMENCING

  • Phase 1 therapeutic about to launch in late stage HER-2+ breast cancer in Germany with Re-188 and Lu-177
  • Can be easily adopted as a therapeutic with Lu-177 or Ac-225
  • High probability of success as a therapeutic agent
  • Patient safety data
  • Same targeting as imaging but just change of war-head ( Tc-99m to Re-188, or Ga-68 to Lu-177 )
  • Re- and Tc- structural and reaction chemistry is the “same” – easy conversion
  • Apply to patients with good images and dosimetry – see then treat

PD-L1 PHASE 1 NON SMALL CELL LUNG CANCER IMAGING HAS BEEN COMPLETED ON 40 PATIENTS

  • PD-L1 is a pan-cancer biomarker and immuno-checkpoint blockers are becoming the most important treatment of multiple cancers
  • Imaging technology is licensed to Lantheus for research collaborations in diagnostic imaging
  • Worldwide exclusive license to Radioharm Theranostics for therapeutic use
  • Imaging done on 40 NSCLC patients in Shanghai General and at Kings College London
  • Approved for Phase 2 Imaging Clinical Trial by MHRA
  • DMF for Imaging filed with FDA in US
  • Easily adopted for therapeutic use
  • High probability of success as therapeutic agent
  • Patients safety data; same cold kit as imaging but just change of war-head
  • Apply to patients with good images – see then treat
Specific uptake in primary tumour and metastatic lesions
Pivalate Clinical Trials

Pivalate Phase 1

Imaging complete in cerebral metastases, glioma, kidney, solid tumors

Pivalate Phase 2

In cerebral metastases, glioma, kidney, solid tumors are opening or underway
AVβ6 Integrin Clinical Trials

AVβ6 BEST-IN-CLASS : PHASE 1a COMMENCED

Biodistribution generally (Healthy subject comparison)
*None of Radiopharm Theranositcs’ product pipeline has received marketing authorization in any jurisdiction. Any use of Radiopharm Theranostic products is on an investigational basis or for use in approved clinical trials.

Sign up to our mailing list.

Receive all the latest news from Radiopharm Theranostics.